Recombinant human interleukin 1 receptor antagonist (ILlra) and 35175, a neutralizing monoclonal antibody (mAb) to the type I mouse IIA receptor, were examined for their ability to bind to IIA receptors (IIARs) on various types of mouse cells and to block immune and inflammatory responses to IIA in vitro and in mice. Ilrlra competed for binding of 125 1-II Jct to type I IIAR present on EL4 thymoma cells, 3T3 fibroblasts, hepatocytes, and Chinese hamster ovary cells expressing recombinant mouse type I IIr1R . The ICso values for Ilr1ra binding (ranging from 2 to 4 ng/ml) were similar to those of IIAce . In contrast, I1rlra bound with very low affinity (IC5o values ranging from 10 to 200 Wg/ml) to cells expressing type II IIAR, i.e., 70Z/3 pre-B cell line and polymorphonuclear leukocytes (PMN) derived from bone marrow and acute inflammatory exudates . The mAb 351`5 bound specifically to type I IIr1R ; no inhibition of 12s1-IIr1a binding to cells having type II HAR was observed with very high concentrations ofantibody. While neither Ilslra nor 351`5 had intrinsic activity in bioassays using T helper D10 .G4 .1 cells and mouse thymocytes, both agents blocked the ability of IIA to stimulate proliferation of these cells . The effects ofIlrlra and 35175 on acute inflammatory responses in mice were also evaluated. IIrlra and 35175 blocked the local accumulation of PMN after intraperitoneal injection ofrIIrlcx . The response to IIA was inhibited when IIJ1ra or 35135 was administered simultaneously with or before administration ofID1. IIAra and 35175 also blocked PMN accumulation after intraperitoneal injection of lipopolysaccharide or proteose peptone, suggesting IDI is important in mediating responses to these agents. In addition, I1r1ra and 35175 significantly blocked the ability of IIA to stimulate egress of PMN from bone marrow, to induce a transient neutrophilia, and to elevate serum levels of hepatic acute phase proteins, IIr6, and corticosterone. Thus, IIr1ra and 35175 competitively inhibit the binding of1Trl to the IIr1R on certain cell types. These two IIrl receptor antagonists act to inhibit biological responses induced by IIA and other inflammatory agents.
Recombinant human interleukin 1 receptor antagonist (ILlra) and 35175, a neutralizing monoclonal antibody (mAb) to the type I mouse IIA receptor, were examined for their ability to bind to IIA receptors (IIARs) on various types of mouse cells and to block immune and inflammatory responses to IIA in vitro and in mice. Ilrlra competed for binding of 125 1-II Jct to type I IIAR present on EL4 thymoma cells, 3T3 fibroblasts, hepatocytes, and Chinese hamster ovary cells expressing recombinant mouse type I IIr1R . The ICso values for Ilr1ra binding (ranging from 2 to 4 ng/ml) were similar to those of IIAce . In contrast, I1rlra bound with very low affinity (IC5o values ranging from 10 to 200 Wg/ml) to cells expressing type II IIAR, i.e., 70Z/3 pre-B cell line and polymorphonuclear leukocytes (PMN) derived from bone marrow and acute inflammatory exudates . The mAb 351`5 bound specifically to type I IIr1R ; no inhibition of 12s1-IIr1a binding to cells having type II HAR was observed with very high concentrations ofantibody. While neither Ilslra nor 351`5 had intrinsic activity in bioassays using T helper D10 .G4 .1 cells and mouse thymocytes, both agents blocked the ability of IIA to stimulate proliferation of these cells . The effects ofIlrlra and 35175 on acute inflammatory responses in mice were also evaluated. IIrlra and 35175 blocked the local accumulation of PMN after intraperitoneal injection ofrIIrlcx . The response to IIA was inhibited when IIJ1ra or 35135 was administered simultaneously with or before administration ofID1. IIAra and 35175 also blocked PMN accumulation after intraperitoneal injection of lipopolysaccharide or proteose peptone, suggesting IDI is important in mediating responses to these agents. In addition, I1r1ra and 35175 significantly blocked the ability of IIA to stimulate egress of PMN from bone marrow, to induce a transient neutrophilia, and to elevate serum levels of hepatic acute phase proteins, IIr6, and corticosterone. Thus, IIr1ra and 35175 competitively inhibit the binding of1Trl to the IIr1R on certain cell types. These two IIrl receptor antagonists act to inhibit biological responses induced by IIA and other inflammatory agents.
T he 1IA proteins, IIrlot and IIAO, are implicated in numerous physiological and pathological host responses to trauma, stress, and infection (1) . Many of the actions of IIA are pro-inflammatory and include the ability ofIIr1 to stimulate prostaglandin E2 (PGE2)1 synthesis (2, 3), collagenase release (2), bone resorption (4), and PMN accumulation (5-7), and 1 Abbreviations used in this paper. APP, acute phase protein; CHO, Chinese hamster ovary; C3, complement component 3 ;11,1ra, interleukin 1 receptor antagonist ; PEC, peritoneal exudate cell ; PGE2, prostaglandin E2; SAP, serum amyloid P.
to induce fever (8) and stimulate the acute phase response (9) . Thus, these responses create the potential for significant IIA-mediated pathology in a number of disease states.
Recently, a human monocyte-derived IIrl inhibitor, designated IIA receptor antagonist (IIrlra), has been identified. The cDNA encoding IlAra has been cloned and rILlra protein has been produced in Escherichia coli (10-12). The rIIrlra binds to the IIr1R on E14 thymoma cells (10) and blocks several IIrl-stimulated responses in vitro, including : (a) PGE2 release by fibroblasts (10), synovial cells, and chondrocytes (13); (b) thymocyte proliferation (12, 13) ; (c) collagenase production by synovial cells (13) ; and (d) leukocyte adherence to endothelial cells (12, 14) .
A rat mAb, 35F5, to the I1AR on mouse EIr4 thymoma cells has recently been described (15) . Antibody 35F5 was shown in initial studies to block the binding of 125 1-ILrl to IIAR on mouse T cells and fibroblasts (15) and to diminish host responses to IIrl and other inflammatory stimuli in vivo (16) (17) (18) .
Recent studies have shown that at least two types of IIr1R are differentially expressed on the surface of certain types o£ murine cells and cell lines (15, 19) . The type I (T cell, fibroblast) receptor, but not to the type II (B cell, macrophage) receptor, appears to selectively bind IIL1ra (10) . Similarly, 35F5 binds solely to the type I IIAR but not the type II IIAR (15) . The binding of 11r1ra or 35F5 competitively antagonizes the binding of radiolabeled Ur1(10, 15) . In the studies reported here, we have extended the observations of earlier reports on the in vitro activity of IIr1ra and 35F5 . In addition, to further our understanding of the biology and pathophysiology of IDl, the effect of these IIs1 inhibitors on the induction of various acute inflammatory reactions in mice was examined .
Materials and Methods
Mice. C57BL/6 and C3H/HeJ female mice, 6-8 wk of age, were obtained from TheJackson Laboratory, Bar Harbor, ME . Mice were maintained in sterilized cages with filter tops and autoclaved food, water, and bedding. Mice were routinely acclimated for at least 1 wk before use.
Reagents. Human rIIr1ra was obtained from Drs. R. Thompson and R. Hageman, Synergen, Inc., Boulder, CO. Human rILlca and rIL10, with specific activities of -3 x 108 U/mg, as determined in the D10.G4.1 cell proliferation assay, were provided by Dr. S. Roy, Hoffmann-LaRoche Inc. Diluent vehicle for in vivo studies was sterile Dulbecco's Cal*-and Mgt*-free PBS (Gibco Laboratories, Grand Island, NY). The 11,1 used in these experiments was shown by Limulus amebocyte lysate assay (Associates of Cape Cod, Woods Hole, MA) to contain <0 .2 ng endotoxin/mg 11,1. The vehicle contained <0 .2 ng endotoxin per 0.1 ml . Proteose peptone (Difco Laboratories, Detroit, MI) was dissolved (3% [wt/vol] ) in endotoxin-screened water (Gibco Laboratories), passed through a 0.45-gM filter, and stored at 4°C until use. LPS (E. coli, strain 026:136) and a purified normal rat IgG preparation were obtained from Sigma Chemical Co ., St . Louis, MO . Purified rat 35F5 mAb (15) was obtained from Drs. R. Chizzonite and A. Stern, Hoffmann-LaRoche Inc. Peritoneal Exudate Cells and Bone Marrow Cells. Peritoneal exudate cells (PEC) were collected after cervical dislocation of mice by injecting 4 ml serum-free RPMI 1640 (Gibco Laboratories) into the peritoneal cavity. After vigorous massage of the abdomen, an aliquot of the medium (33 ml) was withdrawn and the cell concentration was determined on a cell counter (Coulter Electronics, Hialeah, FL). Cytocentrifuge (Shandon, Inc., Pittsburgh, PA) smears of PEC were stained with Wright's stain for differential counts . Total of numbers of PMN accumulating in the peritoneal cavity were calculated by multiplying total PEC by the percent PMN (determined from differential counts).
To determine the effects of 11,1 administration on bone marrow PMN numbers, bone marrow was harvested from both femurs by flushing with HBSS . A single cell suspension was prepared by gently
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Interleukin 1 Receptor Antagonist Blocks Inflammation passing the bone marrow through 18-and then 21-gauge needles. Total nucleated bone marrow cells were determined on a cell counter (Coulter Electronics). Differential counts of bone marrow cells were performed on Wright's-stained cytocentrifuge smears . The percentage of mature PMN (no bands, metamyelocytes, or myelocytes) was used for calculations since preliminary studies showed that injection of 11A (at the doses used) resulted in an increase of only mature PMN in the peripheral blood (data not shown) . Bone marrow cells for binding assays were prepared as described below.
Binding Assays. Human rIL1a was radiolabeled with Na 1 asI using Enzymobeads reagent (Bio-Rad Laboratories, Richmond, CA) as described (20) . Murine E1,4 thymoma cells (T19-181 ; American Type Culture Collection, Rockville, MD) were cultured and membrane fractions prepared as described (20) . Binding experiments were conducted with E1,4 membranes as described previously (20) . Briefly, the I1,1ra, 35F5, or IIr1 proteins (concentrations ranging from 0.01 ng/ml to 6.7 mg/ml as indicated) were pre-incubated with E1,4 membranes for 30 min at 37°C . Radiolabeled 11,1a (30,000 cpm/ml; 20 pM final concentration) was added and the incubation continued for 1 h at 37°C . The assay was terminated by filtration and bound 1211-IILla was determined by use of a gamma counter. Murine 3T3 fibroblast cell line (American Type Culture Collection) was cultured, and binding experiments were performed with monolayer cultures of cells as described (21) . Briefly, confluent, adherent 3T3 cells were incubated with the unlabeled competitor and 115 1-ILla (20,000 cpm/ml, final concentration) for 3 h at 4°C. The cells were washed, detached with SDS-containing buffer, and bound 121 1-I1,1a was determined .
Chinese hamster ovary (CHO) DHFR -cells, transfected with a cDNA (provided by Dr. U. Gubler, Hoffmann-LaRoche Inc.) encoding the mouse type I ILiR and amplified in the presence of methotrexate, express -6,000 mouse IL1R/cell (22) . Confluent cultures of transfected CHO cells in 24-well tissue culture plates (Costar, Cambridge, MA) were incubated with competing ligand in the presence of 121 1_IIAa for 3 h at 4°C. Bound "1 1_ILlca was determined essentially as described for the 3T3 cell line above.
Membranes were prepared from livers obtained from normal C57BL/6 mice . Individual livers were excised, minced with scissors, and homogenized in 25 ml buffer A (10 mM Tris-HCl [pH 7.2], 1 mM EDTA, 1 tag/ml PMSF) in a Polytron homogenizer (Brinkman, Westbury NY). The homogenate was passed through two layers of cheesecloth and twice clarified by centrifugation at 450g for 10 min. Crude membranes were collected from the clarified supernatant by centrifugation at 39,000 g for 30 min. The membrane pellets were resuspended in buffer A and homogenized in a glass-glass Dounce homogenizer. Aliquots of membranes were stored at -80°C. Binding assays with liver membranes were performed as described above for EL4 cell membranes.
The 70Z/3 pre-B lymphocyte cell line (American Type Culture Collection) was maintained as described (15) . Elicited peritoneal exudate cells were collected by peritoneal lavage from mice injected with proteose peptone (7). Femoral bone marrow cells were obtained from mice treated 5 d earlier with 150 mg/kg cyclophosphamide followed by four daily subcutaneous injections of IM (10 ltg/kg). Such bone marrow cells were >50% late-stage granulocytes (metamyelocytes, bands, mature neutrophils) by morphological criteria (23) . Binding assays with 70Z/3, peritoneal exudate cells, and bone marrow cells were performed in 12 x 75-mm polypropylene tubes as described (7, 15) . Cells were incubated with ILlra, 35F5, or IIA proteins (concentrations ranging from 0.01 ng/ml to 6.7 mg/ml) in the presence of 121 1_ILrlca for 3 h at 37°C, and bound "1 1_ILla was determined by centrifugation over oil.
Hematology. Peripheral white blood cells (WBC) were enumerated on a cell counter (Coulter Electronics) . Differential WBC counts were performed on Wright's-stained smears . Absolute PMN numbers were calculated by multiplying the total WBC by the percent PMN obtained from differential counts. Acute Phase Protein Determinations. Concentrations for serum arnyloid P and complement component 3 (C3) were determined by the "rocket" immunoelectrophoresis method of Laurell (24) . Specific antisera and antigen standards were obtained from Calbiochem-Behring Corp., La Jolla, CA, and Organon Teknika Corp., West Chester, PA.
Serum Corticosterone Assay. Mice were quickly (5 s) anesthetized with C02 and bled from the retro-orbital plexus. Blood obtained during the first 15 s was allowed to clot at room temperature and serum was assayed for corticosterone with a commercial RIA kit (ICN Biomedicals, Inc ., Costa Mesa, CA).
IL6 Bioassay. Serum levels of IL6 were determined using a modification of the B9 hybridoma cell assay described previously (25) . Cells were treated with twofold serial dilutions of the test sera in 96-well microtiter plates. After a 3-d incubation at 37°C in a humidified atmosphere of 5% C02 and 95% air, the wells were pulsed with 0 .5 ACi of ['H]TdR and incubated for an additional 18 h. The cells were then harvested onto glass fiber filters and the level of ['H]TdR incorporation was determined using a liquid scintillation counter. 11,6 units are defined as the inverse of the serum dilution that produces half-maximal ['H]TdR incorporation compared with a reference standard.
D10G4 .1 Assay. Mouse T helper D10 .G4 .1 cells (American Type Culture Collection) were originally described by Kaye et al. (26) . Cultures (2 x 10' D10.G4 .1 cells suspended in RPMI 1540 containing 5% FCS, 5 x 10 -5 M 2-ME, 814g/ml gentamicin, 2 mM L-glutamine, and 2 .5 wg/ml Con A) were established in 96-well flat-bottomed tissue culture plates. ILira or 351`5 was added to triplicate cultures 1 h before the addition of IIAci or ILls. The plates were incubated, and incorporation of ['H]TdR was determined as described above for the IIA assay.
Thymocyte Proliferation Assay. C3H/Hej thymorytes (1 .5 x 106) in RPMI 1640 containing 5% FCS, 2 .5 x 10 -5 M 2-ME, 8 ug/ml gentamicin, and 6 wg/ml PHA were added to 96-well microtiter plates. ILira or 351`5 was added to triplicate cultures 1 h before the addition of ILla or ILlO . The plates were incubated, and incorporation of ['H]TdR was determined as described for the 11,6 assay.
Statistical Analysis. Data are presented as the mean ± SD of three to five mice per group. The differences between treatment groups were analyzed by Student's t test (27) and were considered statistically significant at p < 0 .05 .
Results

In Vitro Studies with ILira
Inhibition ofReceptor-Ligand Interactions. ILira was examined for its ability to inhibit binding of 125 1-IL1cY to a number of cells and cell lines (Table 1) . The IC5o values for ILira binding (i.e., concentration of competitor inhibiting binding of 125 1_IL1a by 50%) ranged from 2 to 4 ng/ml in experiments performed with mouse E14 thymoma, 3T3 fibroblast, and CHO cells expressing recombinant mouse type I IL1R . These IC5o values for ILira were similar to those obtained for ILla and ILlf with these same cell types .
The binding of these three ligands to additional cell types 933 McIntyre et al. was examined further. Both ILla and 1140 bound with high affinity to 111R present on the mouse 70Z/3 cell and to protease peptone-elicited mouse peritoneal neutrophils and to granulocytes and granulocyte progenitors obtained from mouse bone marrow. In contrast, ILira bound with very low affinity to these cell types (IC5o values ranging from 10 to 200 1~g/ml) . Inhibition of binding by the IL1 proteins and ILira was specific since concentrations of IL2 up to 1 mg/ml were found to have no effect on the binding of 125 1-ILla to any of the cell types (data not shown) .
The anti-ILIR mAb 351`5 was examined for its ability to block the binding of 125 1-IL1a to IL1R (Table 1) . Antibody 351`5 inhibited the binding of IL1 to the type I IL1R on T cells, fibroblasts, hepatocytes, and CHO cells expressing type I mouse IL1R with an affinity comparable with that of ILira, taking into consideration the -10-fold difference in molecular weight of the two inhibitors . In contrast to ILira, however, antibody 351`5 is highly specific for type I IL1R, as concentrations of 351`5 up to 6 .7 mg/ml failed to inhibit the binding of IIA to IL1R on 70Z/3 cells and inflammatory and bone marrow-derived PMN (Table 1) . This finding was corroborated by studies in which no binding of radiolabeled 125 1-351`5 to IL1R on these cells was detected (data not shown) .
Effect of ILira and 351`5 on III-stimulated T Cell Responses. ILira inhibited, in a dose-dependent manner, the co-mitogenic effect of ILl on D10 .G4 .1 cells and mouse thymocytes (Table 2) . A 1,000-fold molar excess of ILira over IIA was needed to completely block the response to IL1a in bioassays. However, the inhibition by ILira was specific since higher concentrations of ILl could overcome the in- hibitory effect of II,lra . The inhibitory effect of IL1ra on ILlß-induced proliferation was similar to that seen with Mot (data not shown) . mAb 35175 was also tested in these in vitro assays . Antibody 35175 demonstrated a dose-dependent inhibition of proliferation of both D10.G4.1 cells and thymocytes at low concentrations of IL1 (Table 2 ) . These effects of 35175 were reversed at higher concentrations of IL1.
In Vivo Studies with ILira and 35175
Inhibition of ILI-stimulated Induction of IL6 by ILlra. IL Ira inhibited the induction of IL6 by II loi in a dose-dependent manner when IIrlra was injected simultaneously with IIA (Table 3 ) . The inhibition was maximal when >100-fold excess of ILlra over IL1 was administered . Furthermore, inhibition was observed when 10 mg/kg of IIAra was administered simultaneously with or 1-2 h before 10 Wg/kg of IIA; no inhibition was seen when IIL1ra was given 4 h before IL1 (Fig . 1) . Administration of 35175 to mice also blocked induction of IL6 by IL1 (data not shown), confirming previous studies (18) .
Inhibition of Acute Phase Protein Synthesis by ILlra and 35175. The effect of IL1ra on ILI-stimulated increases in Table 3 . IL-Ira Inhibits IL-1-induced Elevation of IL-6 Levels in Serum in a Dose-dependent manner
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Interleukin 1 Receptor Antagonist Blocks Inflammation C57BL/6 mice (four/group) were injected subcutaneously with the indicated dose of IL-lra together with 10 Kg/kg IL-1 . The mice were bled 3 h later and the levels of serum IL-6 were determined . p < 0.05 compared with IL-1 alone.
the hepatic acute phase proteins (APP), serum amyloid P (SAP) and complement component 3 (C3), was examined. A single injection of IIAra given simultaneously with or 15 min before IIA significantly attenuated the increases in SAP and C3 observed 24 h after IIA injection (Fig . 2) . When ILlra was injected 15 min after IL 1, the IL-1-stimulated levels of SAP and C3 were not significantly reduced. Thus, II.-Ira maximally inhibited IL-1-stimulated APP synthesis when given simultaneously with ILl. Significant reductions in IL-1-stimulated SAP levels were also observed upon administration of 35F5 antibody to mice. Increases in serum SAP levels were blocked in a dose-dependent manner by 35175 (Table 4 , Exp. 1) . The inhibition of the 11,1-stimulated increase in SAP was observed when 35175 was administered before, but not after, ILl (Table 4 , Exp. 2) . Anti- Figure 1 . Effect of time of IIArainjection on ability to block induction of serum 11,6 by IL-a . C57BL/6 mice (four/group) were injected with IL lra (5 mg/kg, sc.) at various times relative to injection of IILla (5 ug/kg, sx .) . Mice were bled 3 h after ILl injection and serum 11,6 levels were determined. Control (PBS-injected) mice had no detectable (<20 U/ml) IL-6 (data not shown) . ' p < 0.05 compared with mice receiving no IIArá. body 351`5 has also been shown to modulate SAP levels in mice during inflammation induced by other agents (17). Inhibition of IA-stimulated Adrenal Glucocorticoid Release by 351`5. Antibody 351`5 was tested for its ability to block increases in serum corticosterone induced by IL-1 (Fig. 3) . Com- In exp. 1, C57BL/6 mice (four/group) were injected subcutaneously with various doses of 351`5 antibody 4 h before subcutaneous injection of IL-la (5 .0 pg/kg) . Mice were bled 24 h after IL-1 injection for SAP determinations. In exp. 2, C57BL/6 mice (four/group) were injected subcutaneously with 351`5 (10 mg/kg) at the indicated times before or after subcutaneous injection of IL-la (5 .0,ug/kg) . Mice were bled 24 h after IL-1 injection for SAP determinations . p < 0.05 compared with IL-1 .
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McIntyre et al . (Table 5 , Exp. 1) . Injection of IL1ra alone caused no change in peripheral blood leukocyte numbers (data not shown) . In addition to stimulating an increase in numbers of PMN in the blood, injection of II,1 induced a reciprocal decline in numbers of PMN in the bone marrow. This depletion of bone marrow PMN was largely blocked by treatment with IIrlra . Treatment of mice with 10 mg/kg of 351`5, but not a control preparation of purified rat IgG, blocked both relative and absolute neutrophilia induced by injection of IL-1 (Table 5, Exp. 2).
Inhibition of IL1-induced PMN Accumulation by ILlra. To study the effect of ILlra on IIA-induced PMN accumulation, mice were treated with IILlra at various times relative to the injection of 5 .0 ng/kg of ILlot . The data in Fig. 4 demonstrate that IL1ra must be administered at the time of, or shortly before, ILA injection in order to inhibit PMN accumulation in response to IIA . Thus, accumulation of PMN in response to IIA was significantly inhibited in mice treated with IIAra at the same time as or 10 min before IL1 injection . The inhibitory effects of ILlra were markedly diminished when ILlra was administered 30 min before IL1. Furthermore, ILlra was unable to block the PMN influx when given 10 min after IL1 . When tested over a range of doses (50 pg/kg to 5 mg/kg), injection of IIr1ra alone did not elicit In Exp. 1, mice (three/group) were injected intraperitoneally with 0.1 ml PBS (control), 0.1 ml PBS containing either 0.5 !cg/kg of IL-1a or 0.5 pg/kg of IL-la, plus 5 mg/kg of IL-lra . In Exp. 2, mice (five/group) were injected subcutaneously with 10 mg/kg of purified rat IgG or 35F5 antibody 18 h before intraperitoneal injection with 5 ííg/kg of IL-1a. Mice were bled 4 h after IL-1 injection and absolute numbers and percentages of PMN in peripheral blood and in femoral bone marrow were determined. p < 0.05 compared with control. t p < 0.05 compared with IL-la alone.
PMN influx (data not shown) . Other routes of administration for I1r1ra were also highly effective at blocking localized peritoneal responses to IIrl. Parenteral (subcutaneous or intravenous) administration of IIAra just before intraperitoneal injection of IIA also blocked accumulation of PMN (data not shown) .
Inhibition of LPS-and Proteose Peptone-induced PMN Accumulation by II lra and 35F5. The effects of I1rlra and 35F5 on acute inflammatory responses to LPS and proteose peptone were studied . Mice were injected with IIAra or 35F5 and then injected with LPS (5 wg/kg) or sterile proteose peptone (1 .0 ml, 3% solution) . As shown in Fig. 5 , both IIAra and 35F5 significantly inhibited PMN influx induced by both of these agents, suggesting that IIA mediates this PMN response Figure 4 . Time of IlAra injection affects ability to inhibit PMN influx . Mice (three/group) were injected intraperitoneally with either PBS (control) or ILl (5 ng/kg, all other groups). Individual groups were injected intraperitoneally with I1Jlra (5 mg/kg) at various times relative to IIA injection as shown. PEC were collected from all mice 4 h after IIA injection and total PMN determined . * p < 0.005 compared with IIrl alone.
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Interleukin 1 Receptor Antagonist Blocks Inflammation to LPS and proteose peptone. In repeated experiments, IIr1ra and 35F5, even at high dose (50 mg/kg), only partially blocked (55-80%) the response to LPS and proteose peptone, whereas the PMN influx in response to IIrl can often be virtually eliminated with l1rlra (McIntyre et al ., unpublished observations) . These findings suggest that factors in addition to IIrl may be involved in regulating PMN accumulation in vivo in response to LPS and proteose peptone. Hannum et al. (10) showed that II, lra binds to IIAR present on E14 thymoma cells with an affinity approximately equal to that for human IIA0. Our experiments show that IIrlra also inhibits binding of t25I-Ilrla to membranes prepared from El4 cells with an ICso of x+2 .0 ng/ml . This value is comparable with those obtained for IIrla and Ills (2 .0 and 10 .0 ng/ml, respectively) . In addition, Illra bound with high affinity to the Il1R present on the 3T3 fibroblast cell line and to mouse rI11R expressed by CHO cells. The I11R present on EIr4 and 3T3 cells is identical to that which has been cloned and expressed in CHO cells and has been tentatively designated as the T cell/fibroblast, or type I, IIr1R (15, 19) . A second type of IIAR, designated the B cell/macrophage or type II ID1R, is present on murine macrophage and B cell lines and on PMN and PMN progenitors (15, 19) . Studies by Hannum et al . (10) and Carter et al. (12) suggest that IIrIra binds to the type I IIAR but not to the type II IIAR . In this report, high concentrations of I11ra were evaluated in competitive inhibition experiments using 70Z/3 pre-B cells, proteose peptone-elicited peritoneal exudate cells, and bone marrow cells. Our results show that IIrlra blocks binding of radiolabeled IIrlot to the type II mouse I11R at very high concentrations. An ICso of 30 lAg/ml was obtained for 70Z/3 cells . A concentration of 200 lAg/ml of I1r1ra was found to inhibit binding of IIrla to proteose peptone-elicited peritoneal exudate cells or bone marrow cells by 50%. Previous work has shown that PMN in the peritoneal exudate cell population (7) and granulocytes and granulocyte progenitors in bone marrow (K.P. Parker, K .W. McIntyre, and P.L . Kilian, unpublished observations) are the cells expressing IDIR . We conclude from these binding experiments that IIx1ra binds with high affinity to the type I IIAR and with a greatly reduced affinity to the type II I11R .
The receptor binding experiments with 35175 confirm and extend previous observations (15) that this antibody specifically recognizes the type I IIAR and shows no detectable inhibitory activity on type II I11R even at high concentrations (Table 1) . This finding has important implications for the interpretation of the in vivo experiments with IIrlra reported here. In the responses examined, a large molar excess of Il 1ra over Ill (102 -to 105-fold) is often necessary to achieve significant inhibition . This raises the question of whether the IIAra at these high doses may bind to type II 111R in vivo, thereby inhibiting Ill-induced responses through interaction with type II IIr1R. However, this possibility is unlikely inasmuch as the type I IIAR-specific 35175 antibody reproduces the inhibitory activities of IIAra in vivo (and in vitro) . These findings confirm the proposition that suppression of these Ill-stimulated responses is mediated through interactions with the type I IIr1R .
The studies on stimulation of thymocyte and D10 .G4 .1 cell proliferation by Ill suggest that very few IIr1Rs need to be occupied by Ill in order to elicit a biological response. Proliferation of D10.G4.1 cells is stimulated by 11,1 concentrations that are substantially lower than the ICso obtained for Ill in receptor binding assays . Similar findings were reported for Ill-stimulated production of Il2 by E14 cells 93 7 McIntyre et al. (28) and suggest that a large proportion of I11R on cells are present as "spare receptors". Based on these findings, it would seem likely that near saturation of IIAR with I1r1ra would be required to achieve antagonist activity (13). This, in turn, probably explains why a high molar excess of IIrlra or 35175 over IIr1 was needed to block the effects of Ill in vivo. APP synthesis by the liver during inflammation is regulated by the concerted action of multiple soluble mediators . The presence of I11, 116, and adrenal glucocorticoids is required for maximal stimulation of APP synthesis by hepatocytes in vitro (29) . This condition is met in vivo where injection of Ill into mice stimulates increased levels of both IIr6 and glucocorticoids. However, IIAra (Fig. 1) and 35F5 (18) prevent the induction of IL-6, and both Il1ra (12) and 35175 (Fig . 3) block corticosterone release . In addition, these type I IIr1R antagonists block the binding of Ill to I1r1R on liver cells (Table 1) . Thus, the combined action of the three signals important for the stimulation of hepatic APP synthesis is suppressed by Illra and 35175, resulting in inhibition of this IIr1-stimulated response (Fig. 2, Table 4 ) .
The appearance of PMN at sites of inflammation is the result of a coordinated series of events . These steps may include release of PMN from bone marrow into the circulation, their adherence to endothelial cells, and then their subsequent migration into adjacent tissues. The release of PMN from bone marrow and the subsequent neutrophilia induced by Ill injection are suppressed by ILlra (Table 5) . However, IIrlra failed to reduce Ill-stimulated neutrophilia in other studies (12) using a higher dose of Ill than that used here. That failure of IIr1ra to inhibit neutrophilia (possibly due to an insufficient molar excess of I11ra) led to the suggestion that the type II IIAR was mediating this response (12). However, our current data with IIr1ra and 35175 demonstrate that Ill-stimulated neutrophilia is indeed blocked by type I IL 1R antagonists.
Adhesion of PMN to endothelial cells is a step crucial in PMN accumulation (30, 31) . Adhesion is augmented by 11,1 through increased expression of adhesion glycoproteins on endothelial cells (31) , and I1r1ra pretreatment of endothelial cells blocks this response (14) . Accumulation of PMN is further stimulated by the localized generation of factors chemotactic for PMN . The PMN chemotactic factor I18 (33) is synthesized by fibroblasts (34, 35) and endothelial cells (36) upon exposure to ID1 . Since these cell types express type I IIAR, I1r1ra may be able to block this response as well. Thus, in mediating its inhibition of PMN accumulation, Il1ra may act at three steps in the inflammatory pathway by : (a) blocking PMN release from bone marrow and the resulting neutrophilia; (b) blocking endothelial cell/PMN adhesion ; and (c) blocking the generation of specific PMN chemotactic factors .
Our results also demonstrate that Illra and 351`5 block PMN accumulation in response to the nonspecific stimuli LPS and proteose peptone . This holds significance for the mechanism of action of various stimuli in mediating acute inflammatory cell infiltration. The ability of IIr1ra and 35175 to inhibit PMN influx after injection of proteose peptone or LPS strongly suggests that ILA is an important participant in these responses. However, ILI does not appear to be the sole responsible mediator since IL1ra and 35F5 fail to completely block PMN accumulation . Other factors such as complement component fragments and leukotrienes are chemotactic for PMN, and these factors may be generated by IL1-independent mechanisms after injection of proteose peptone or LPS.
In summary, our experiments show that human rIL1ra binds with very high affinity to the type I IL1R and with a greatly reduced affinity to type II IL1R . In contrast, 35F5 anti-IL1R mAb is highly specific for the type I IL1R . ILlra References 1 .
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and 35F5 antibody inhibit a wide variety of ILl-stimulated physiological responses in vivo. Both ILlra and 35F5 also modulate responses to nonspecific inflammatory stimuli, implying a role for ILI in these models . Furthermore, these data demonstrate that the type I IL 1R represents the predominant signaling pathway for many host responses attributed to ILI. The role of the type II IL1R in normal or pathological conditions is unclear. Elucidation of its physiological function awaits the identification of antagonists (or agonists) specific for the type II IL 1R .
